Megan Hanna

University of Florida — United States

Medicine · Health Sciences

18h-index11.6kcitations59works4.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(16), Chronic Lymphocytic Leukemia Research(16), Cancer Genomics and Diagnostics(15), Glycosylation and Glycoproteins Research(9), RNA modifications and cancer(6)

Publications59 total

DNA-guided CRISPR/Cas12 for RNA targeting
2024· 4 citedOpen Access
Supplementary Figures 1-7 from Mutations in the <i>DDR2</i> Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer
2023Open Access
Data from Mutations in the <i>DDR2</i> Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer
2023Open Access
Supplementary Figure Legends 1-7 from Mutations in the <i>DDR2</i> Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer
2023Open Access
Supplementary Figure Legends 1-7 from Mutations in the <i>DDR2</i> Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer
2023Open Access
Data from Mutations in the <i>DDR2</i> Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer
2023Open Access
Interview with Dr. Meyerson from Mutations in the <i>DDR2</i> Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer
2023Open Access
Interview with Dr. Meyerson from Mutations in the <i>DDR2</i> Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer
2023Open Access
Supplementary Table 1 from Mutations in the <i>DDR2</i> Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer
2023Open Access
Supplementary Figures 1-7 from Mutations in the <i>DDR2</i> Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer
2023Open Access
Supplementary Table 1 from Mutations in the <i>DDR2</i> Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer
2023Open Access
Data from Integrative Genomic Analysis Implicates Gain of <i>PIK3CA</i> at 3q26 and <i>MYC</i> at 8q24 in Chronic Lymphocytic Leukemia
2023Open Access
Supplementary Table 6 from Integrative Genomic Analysis Implicates Gain of <i>PIK3CA</i> at 3q26 and <i>MYC</i> at 8q24 in Chronic Lymphocytic Leukemia
2023Open Access
Supplementary Methods, Figures 1-4 and Tables 1 - 5, 7 - 15 from Integrative Genomic Analysis Implicates Gain of <i>PIK3CA</i> at 3q26 and <i>MYC</i> at 8q24 in Chronic Lymphocytic Leukemia
2023Open Access
Supplementary Table 6 from Integrative Genomic Analysis Implicates Gain of <i>PIK3CA</i> at 3q26 and <i>MYC</i> at 8q24 in Chronic Lymphocytic Leukemia
2023Open Access
Data from Integrative Genomic Analysis Implicates Gain of <i>PIK3CA</i> at 3q26 and <i>MYC</i> at 8q24 in Chronic Lymphocytic Leukemia
2023Open Access
Supplementary Methods, Figures 1-4 and Tables 1 - 5, 7 - 15 from Integrative Genomic Analysis Implicates Gain of <i>PIK3CA</i> at 3q26 and <i>MYC</i> at 8q24 in Chronic Lymphocytic Leukemia
2023Open Access
Author Correction: Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers
Nature Medicine·2019· 7 cited
Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers
Nature Medicine·2019· 513 cited
Abstract LB-257: Liquid biopsy versus tissue biopsy to assess acquired resistance and tumor heterogeneity in gastrointestinal cancers
Experimental and Molecular Therapeutics·2019
page 1 of 3Next →

Frequent Co-authors

Matthew Meyerson(21), Laura E. MacConaill(20), Gad Getz(15), Charlie Hatton(14), Bethany Tesar(14), Donna Neuberg(14), Arnold S. Freedman(14), Heidi Greulich(13), Jennifer R. Brown(13), Lillian Werner(13), Stacey M. Fernandes(13), Wendy Winckler(12), Michael S. Lawrence(11), Alex H. Ramos(11), Nathalie Pochet(11), Catherine J. Wu(11), Mick Correll(11), Aviv Regev(11), Robert C. Onofrio(10), Roman K. Thomas(10)